|
Prostate:
-
CTSU C90202: A Randomized, Double-Blind,
Placebo-Controlled Phase III Study of Early versus Standard
Zoledronic Acid to Prevent Skeletal Related Events in Men
with Prostate Cancer Metastatic to Bone.
-
SWOG 0421: Phase III Study of Docetaxel and Atrasentan
Versus Docetaxel and Placebo for Patients with Advanced
Hormone Refractory Prostate
Bladder:
-
SWOG 0353: Phase II Study of Intravesical Gemcitabine in
Patients with Superficial Bladder Cancer Who Have Progressed
Despite Intravesical BCG
Renal Cell:
-
CTSU E2805: A Randomized Phase III Trial of Adjuvant
SU011248 (Suitinib), BAY 43- 9006 (Sorafinib) vs Placebo in
Patients with Resected Renal Cell Carcinoma.
-
CTSU E2804: The BeST Trial: A Randomized Phase II study
of VEGF, RAF Kinase, mTOR Comination Targeted Therapy (CTT)
with Bevacizumab, Sorafenib, Temsirolimus in Advanced Renal
Cell Carcinoma
For more information on the above clinical
trials:
Cheryl Patz, RN, OCN, CCRC, 360.715.4133
Return to previous page
|